On September 3, New Ocean Pharmaceuticals announced the completion of Series B overfinancing of more than 80 million US dollars. Participants in this round of financing include B Capital, Junlian Capital, Jingwei Venture Capital, Zhenmai Investment, and Shanghai SDIC Pilot. The original shareholder Eli Lilly Asia Fund continued to invest more. According to New Ocean Pharmaceuticals, this round of funding will focus on expanding the company's innovative pipeline layout in the central nervous system field, speeding up the global clinical development process for core projects, and exploring treatment paths with breakthrough potential around the world's major unmet clinical needs.

On September 3, New Ocean Pharmaceuticals announced the completion of Series B overfinancing of more than 80 million US dollars. Participants in this round of financing include B Capital, Junlian Capital, Jingwei Venture Capital, Zhenmai Investment, and Shanghai SDIC Pilot. The original shareholder Eli Lilly Asia Fund continued to invest more. According to New Ocean Pharmaceuticals, this round of funding will focus on expanding the company's innovative pipeline layout in the central nervous system field, speeding up the global clinical development process for core projects, and exploring treatment paths with breakthrough potential around the world's major unmet clinical needs.